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ABSTRACT
Objective To assess pooled golimumab safety up to year
3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and
ankylosing spondylitis (AS) trials.
Methods Golimumab 50 and 100 mg, administered
subcutaneously (SC) every 4 weeks (q4wk), were assessed
in patients with active RA (methotrexate-naïve,
methotrexate-experienced and anti-TNF (tumour necrosis
factor)-experienced), PsA or AS, despite conventional
therapy. Placebo control continued up to week (wk) 24 (wk
52, methotrexate-naïve), with early escape at wk 16 (wk
28, methotrexate-naïve); subsequently, all patients received
golimumab 50 or 100 mg q4wk. After the blinded
controlled period, golimumab doses could be adjusted per
investigator discretion. Pooled safety analyses reported
herein include data from placebo-controlled and
uncontrolled study periods up to wk 160. Determinations
of incidences/100 patient-years (pt-yrs) for rare events also
included RA patients from a phase IIb trial.
Results Across ﬁve phase III trials of SC golimumab, 639
patients received placebo and 2226 received golimumab
50 mg (n=1249) and/or 100 mg (n=1501) up to wk 160
(patients may be included in more than one group because
non-responders were allowed early escape); 1179 patients
were treated for ≥156 weeks. For placebo, golimumab
50 mg and golimumab 100 mg, respective adverse event
incidences/100 pt-yrs (95% CIs) up to wk 160 were: 0.28
(0.01 to 1.56), 0.30 (0.12 to 0.62), 0.41 (0.23 to 0.69)
for death; 5.31 (3.20 to 8.30), 3.03 (2.36 to 3.82), 5.09
(4.36 to 5.90) for serious infection; 0.00 (0.00 to 0.84),
0.17 (0.05 to 0.44), 0.35 (0.18 to 0.62) for tuberculosis;
0.00 (0.00 to 0.84), 0.13 (0.03 to 0.38), 0.24 (0.10 to
0.46) for opportunistic infection; 0.00 (0.00 to 0.84), 0.00
(0.00 to 0.13), 0.12 (0.03 to 0.30) for demyelination; and
0.00 (0.00 to 0.84), 0.04 (0.00 to 0.24), 0.18 (0.06 to
0.38) for lymphoma.
Conclusions SC golimumab safety up to 3 years
remained consistent with that of other TNF antagonists.
Golimumab 100 mg showed numerically higher incidences
of serious infections, demyelinating events and lymphoma
than 50 mg; safety follow-up up to year 5 continues.
INTRODUCTION
Rheumatoid arthritis (RA), psoriatic arthritis (PsA)
and ankylosing spondylitis (AS) are disorders charac-
terised by excessive production of proinﬂammatory
cytokines, including tumour necrosis factor-α (TNF),
and patients with these chronic diseases receive treat-
ment for a protracted time. After approximately 12–
15 years of clinical use, the safety proﬁle of anti-TNF
agents is generally well characterised and consistent
across agents, including adalimumab,1 certolizumab,2
etanercept3 and inﬂiximab.4
As a more recently developed TNF antagonist, the
human monoclonal antibody, golimumab, has not
been studied as extensively. To date, however, golimu-
mab safety appears to be consistent with that of older
agents.5–7 The pivotal phase III trials of subcutaneous
(SC) golimumab in patients with RA, PsA and AS
comprised randomised, double-blind, placebo-
controlled periods, followed by long-term extensions
designed to evaluate safety up to 5 years. Herein, we
report the safety ﬁndings up to 3 years of golimumab
treatment pooled across these clinical trials.
PATIENTS AND METHODS
Study patients and designs
All clinical trials contributing data to this pooled ana-
lysis were conducted according to the Declaration of
Helsinki and the International Committee on
Harmonisation of Good Clinical Practices. Study
protocols were approved by either central or individ-
ual site institutional review boards/ethics committees;
all patients provided written informed consent before
study participation. Details of patient selection cri-
teria and study designs for each trial have been
reported.8–20
Data from a phase IIb trial in RAwere included in
these pooled analyses for determining the incidences
of rare but important events, as four patients in this
smaller trial had a malignancy (three with non-
melanoma skin cancers (NMSCs) and one with lung
cancer). The duration of the phase IIb trial was
6 months, rather than the 3 years of follow-up for
the phase III trials. The phase IIb trial was therefore
not included in the analyses of more common
adverse events (AEs). See table 1 and online supple-
mentary text for further details of patients/trial
designs.
Data collection and analyses
All AEs were systematically captured and cate-
gorised by the site investigator for seriousness,
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Table 1 Golimumab clinical trials contributing data to 3-year pooled safety analyses
Trial phase/identifier Indication Study design Study treatment
Patients randomised/
treated
Phase IIb8 (for rare
events only)
RA, inadequate response to MTX Multicentre, randomised (1:1:1:1:1), double-blind,
placebo-controlled, 5-arm, dose-ranging study
Fixed SC doses of placebo or golimumab
▸ Placebo+MTX: wk 0 and q2w to wk 18 with crossover to IV infliximab (3 mg/kg) at wks
20, 22, and 28, and then q8w to wk 44
▸ Golimumab 50 mg+MTX: wk0 and q4w to wk 0 and wk 48
▸ Golimumab 50 mg+MTX: wk 0 and q2w to wk 18, then q4w wks 20–48
▸ Golimumab 100 mg+MTX: wk 0 and q4w to wk 48
▸ Golimumab 100 mg+MTX: wk 0 and q2w to wk 18, then q4w for wks 20–48
Placebo: 35/34
Golimumab: 137/137
Total: 172/171
Phase III, GO-BEFORE9 10 RA, MTX-naïve Multicenter, randomised (1:1:1:1), double-blind,
placebo-controlled to wk 52 with early escape* at
wk 28, followed by open-label golimumab from
wk 52 DBL forward
Fixed SC doses of placebo or golimumab
▸ Placebo+MTX q4w
▸ Golimumab 100 mg q4w+placebo
▸ Golimumab 50 mg q4w+MTX
▸ Golimumab 100 mg q4w+MTX; All to wk 52 with early escape at wk 28*
Beginning at wk 52, placebo+MTX-treated pts crossed over to golimumab 50 mg+MTX,
During the OLE, the investigator could escalate open-label golimumab to 100 mg and/or
adjust the MTX dose
Placebo: 160/160
Golimumab: 477/474
Total: 637/633
Phase III,
GO-FORWARD11–13
RA, inadequate response to MTX Multicentre, randomised (3:3:2:2), double-blind,
placebo-controlled to wk 24 with early escape* at
wk 16, followed by blinded golimumab to wk 52
and then open-label golimumab from wk 52 DBL
forward
Fixed SC doses of placebo or golimumab
▸ Placebo+MTX q4w
▸ Golimumab 100 mg q4w+placebo
▸ Golimumab 50 mg q4w+MTX
▸ Golimumab 100 mg q4w+MTX; All to wk 24 with early escape at wk 16*
Beginning at wk 24, placebo+MTX-treated pts crossed over to double-blind golimumab
50mg+MTX
During the OLE, the investigator could escalate open-label golimumab to 100 mg and/or
adjust the MTX dose
Placebo: 133/133
Golimumab: 311/311
Total: 444/444
Phase III, GO-AFTER14 15 RA, inadequate response to
anti-TNF
Multicentre, randomised (1:1:1), double-blind,
placebo-controlled to wk 24 with early escape* at
wk 16, followed by open-label golimumab after
wk 24 DBL
Fixed SC doses of placebo or golimumab
▸ Placebo q4w
▸ Golimumab 50 mg 4w
▸ Golimumab 100 mg q4w; All to wk 24 with early escape at wk 16*
Beginning at wk 24, placebo-treated pts crossed over to golimumab 50 mg
During the OLE, the investigator could escalate open-label golimumab to 100 mg
Placebo: 155/155
Golimumab: 306/306
Total: 461/461
Phase III, GO-REVEAL16–18 PsA, inadequate response to
DMARDs/NSAIDs
Multicentre, randomised (1:1.3:1.3), double-blind,
placebo-controlled to wk 24 with early escape* at
wk 16, followed by blinded golimumab from wk
24 forward. Blinded therapy continued to wk 52
DBL, after which the long-term OLE began
Fixed SC doses of placebo or golimumab
▸ Placebo
▸ Golimumab 50 mg q4w
▸ Golimumab 100 mg q4w; All to wk 24 with early escape at wk 16*
Beginning at wk 24, placebo-treated pts crossed over to golimumab 50 mg
During the OLE, the investigator could escalate the golimumab dose to 100 mg
Placebo: 113/113
Golimumab: 292/292
Total: 405/405
Phase III, GO-RAISE19 20 AS, inadequate response to
DMARDs/NSAIDs
Multicentre, randomised (1:1.8:1.8), double-blind,
placebo-controlled to wk 24 with early escape* at
wk 16, followed by dose-blinded golimumab from
wk 24 forward. Blinded therapy continued to wk
104 DBL, after which the long-term OLE began
Fixed SC doses of placebo or golimumab
▸ Placebo
▸ Golimumab 50 mg q4w
▸ Golimumab 100 mg q4w; All to wk 24 with early escape at wk 16*
Beginning at wk 24, placebo-treated pts crossed over to golimumab 50 mg
During the OLE, the investigator could escalate the golimumab dose to 100 mg
Placebo: 78/78
Golimumab: 278/277
Total: 356/355
*For patients meeting the early escape criteria (ie, <20% improvement in tender and swollen joint counts for RA, <10% improvement in tender and swollen joint counts for PsA, <20% improvement in total back and morning stiffness for AS), those receiving
placebo escaped to golimumab 50 mg, those receiving golimumab 100 mg+placebo added MTX, those receiving golimumab 50 mg increased the golimumab dose to 100 mg, and those receiving golimumab 100 mg had no change in study medication.
AS, ankylosing spondylitis; DBL, database lock; DMARD, disease-modifying antirheumatic drug; IV, intravenous; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; OLE, open-label extension; PsA, psoriatic arthritis; pt, patient; RA, rheumatoid
arthritis; SC, subcutaneous; TNF, tumour necrosis factor; q2/4/8w, every 2/4/8 weeks; wk, week.
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intensity, causality and action taken. Investigators were also
required to document whether or not each AE represented an
infection or injection-site reaction (ISR). AEs were summarised
and categorised by system-organ class using the Medical diction-
ary for regulatory activities, V.12.1.
Aggregate AE-reporting rates were analysed across the trials
based on treatment received (placebo/golimumab dose) before
the AE. Safety events from the ﬁrst golimumab exposure to the
end of the 16-week placebo-controlled period and 3-year
reporting period common to the phase III trials were included.
See the online supplement for further details of data collection/
analyses.
RESULTS
Extent of exposure
Across these ﬁve phase III trials evaluating SC golimumab, 639
patients received placebo, 1249 received golimumab 50 mg, and
1501 received golimumab 100 mg (table 2). Some patients are
counted in more than one treatment group because they
escaped early, crossed over between treatment arms, and/or esca-
lated the golimumab dose.
Baseline patient characteristics
The baseline patient demographics have been reported for each
phase III RA,9 11 14 PsA16 and AS19 trial. Of the 2303 patients,
356 (15.5%) had AS, 405 (17.6%) had PsA, and 1542 (67.0%)
had RA. Baseline disease characteristics of mean C-reactive
protein level (2.0 mg/dL) and Health Assessment Questionnaire-
Disability Index score (1.4) conﬁrm that the overall pooled
safety population entered the trials with inﬂammation and mod-
erate functional impairment (table 3).
Adverse events
During the 16-week placebo-controlled period, similar propor-
tions of patients in the placebo (64.2%), golimumab 50 mg
(67.9%) and golimumab 100 mg (65.7%) groups experienced
≥1 AE. Infection was the most common AE; only upper respira-
tory tract infection, nasopharyngitis and nausea occurred in
>5% of patients in either golimumab group. Up to week (wk)
16 in the placebo, 50 mg and 100 mg groups, 4.9%, 4.4% and
3.6%, respectively, of patients experienced ≥1 serious AE (SAE),
and 2.8%, 2.6% and 1.8% of patients, respectively, discontin-
ued the study agent because of ≥1 AE (table 4). Infection was
also the most commonly occurring SAE.
Up to wk 160, ≥1 AE was reported by 73.6%, 85.6% and
86.7% of patients receiving placebo (average length of
follow-up 28.1 weeks), golimumab 50 mg (93.4 weeks) and goli-
mumab 100 mg (115.1 weeks), respectively (table 4). Overall
AEs were generally evenly distributed across disease states, as
were the most commonly occurring types of AEs (see online
supplementary table S1).
The AEs occurring in >5% of patients in any treatment
group up to wk 160 were similar to those observed during the
placebo-controlled period. Across all treatment groups, infec-
tions were again the most common (placebo, 34.6%; 50 mg,
60.4%; 100 mg, 64.3%). Although the proportion of patients
with infection in each golimumab group was nearly twice as
high as that in the placebo group, the duration of golimumab
follow-up was ≥3 times longer than that for placebo. The time-
adjusted incidence of serious infection was higher for golimu-
mab 100 mg (5.09/100 pt-yrs) than for golimumab 50 mg
(3.03/100 pt-yrs); however, the incidence observed with placebo
(5.31/100 pt-yrs) was the highest among the three groups up to
160 weeks; a similar pattern was observed during the placebo-
controlled period (table 5). Serious infections appeared to be
more common among golimumab-treated patients with RA
(147/1616, 9.1%) than among golimumab-treated patients with
PsA (10/394, 2.5%) or AS (17/353, 4.8%). Within each indica-
tion, the 95% CIs surrounding serious infection incidence rates
for golimumab 50 mg and 100 mg were contained within those
for placebo (see online supplementary table S1). Serious infec-
tions, but not all infections or opportunistic infections, also
appeared to occur more commonly among golimumab-treated
patients with baseline oral corticosteroid use versus patients not
using corticosteroids at baseline, although the 95% CIs did
overlap, at both wk 24 and wk 160 (see online supplementary
table S2).
Higher incidences of tuberculosis (0.35 vs 0.17/100 pt-yrs)
and opportunistic infection (0.24 vs 0.13/100 pt-yrs) were
observed with golimumab 100 mg than with golimumab 50 mg;
the 95% CIs for both golimumab doses, however, were con-
tained within those for placebo for both of these AEs up to
160 weeks (table 5). Of the patients with tuberculosis, 15 had
RA and one had AS (see online supplementary table S1).
Pulmonary tuberculosis was the most common presentation, and
all patients were located outside of North America (Asia,
Europe and South America).
Up to wk 160, with a far longer period of follow-up for goli-
mumab than for placebo treatment, 57 (8.9%), 192 (15.4%)
and 325 (21.7%) patients in the placebo, golimumab 50 mg and
golimumab 100 mg groups, respectively, had ≥1 SAE, and 31
(4.9%), 92 (7.4%) and 158 (10.5%) patients, respectively, dis-
continued the study agent because of an AE (table 4). Up to wk
160, 22 patients died, including one (0.1%), seven (0.5%) and
14 (0.9%) patients in the placebo, golimumab 50 mg and
golimumab 100 mg groups, respectively. The time-adjusted
Table 2 Extent of exposure: pooled data from five phase III studies of SC golimumab in RA, PsA and AS
Placebo±MTX Golimumab 50 mg±MTX Golimumab 100 mg±MTX
Number of treated patients* 639 1249 1501
Number of SC injections (mean/median) 6.6/6.0 22.4/22.0 27.5/35.0
Weeks of follow-up (mean/median) 28.1/24.0 93.4/100.0 115.1/144.6
Cumulative golimumab dose (mean/median), mg N/A 1118.6/1100.0 2739.9/3500.0
Number (%) of patients by length of golimumab exposure
<104 weeks N/A 663 (53.1) 604 (40.2)
104 to <156 weeks N/A 323 (25.9) 200 (13.3)
≥156 weeks N/A 263 (21.1) 697 (46.4)
*Patients may appear in ≥1 treatment column.
AS, ankylosing spondylitis; MTX, methotrexate; N/A, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SC, subcutaneous.
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incidence of death was 0.52/100 pt-yrs for the placebo-
controlled period and 0.41/100 pt-yrs up to wk 160 for patients
who received golimumab 100 mg, which was numerically
higher than for patients who received golimumab 50 mg (0.27
and 0.30/100 pt-yrs, respectively); the 95% CIs for the 100 mg
group, however, were contained within that for placebo at both
time points (table 5). Fourteen of the 22 deaths occurred between
wk 52 and wk 160. Causes of death were cerebrovascular/
cardiovascular event in six patients, malignancy in ﬁve patients,
infection in three patients, hypoglycaemic coma in one patient,
hepatitis in one patient, an unrelated accident in one patient,
and an overdose in one patient; the cause of death was
unknown for four patients. More golimumab-treated patients
with RA (19/1616, 1.2%) died than did golimumab-treated
patients with PsA (2/394, 0.5%) or AS (0/353, 0.0%). Within
each indication, the 95% CIs surrounding death incidence rates
for golimumab 50 mg and 100 mg were contained within those
for placebo (see online supplementary table S1).
The overall incidence of malignancy up to wk 160 did not
appear to be elevated with golimumab vs placebo treatment,
with golimumab 100 mg vs 50 mg, or when compared with
rates expected in the general US population. Similar ﬁndings
were observed for NMSC. A higher incidence of lymphoma was
observed up to wk 160 with golimumab 100 mg (0.18/100
pt-yrs) than with golimumab 50 mg (0.04/100 pt-yrs) or
placebo (0.00/100 pt-yrs), and also relative to the general US
population (standardised incidence ratio (SIR) of 6.69 and sur-
rounding 95% CI of (2.45 to 14.56), which was not inclusive of
1; table 5). The higher incidence of lymphoma in golimumab-
treated patients was driven by that in patients with RA (SIR
(95% CI) of 5.70 (2.09 to 12.42)) (see online supplementary
table S1).21–25 No predominant time point at which the lymph-
omas occurred was observed: two cases of lymphoma occurred
during year 1, two occurred during year 2, one occurred during
year 3, and two occurred during year 4.
Up to wk 160, the number of golimumab-treated patients who
experienced ≥1 AE associated with the following selected auto-
immune disorders were: lupus-like syndrome, one (0.0%); sys-
temic lupus erythematosus, one (0.0%); pustular psoriasis, 11
(0.5%); vasculitic rash, four (0.2%); and anti-neutrophil cytoplas-
mic antibody-positive vasculitis, one (0.0%). No patient in the
placebo group experienced any such event. No anaphylactic events
or serum sickness-like reactions were reported up to wk 160.
Up to wk 160, four demyelination events were identiﬁed in
three patients randomised to golimumab 100 mg, all of whom had
RA, with none occurring among patients randomised to either
Table 3 Baseline patient demographic and disease characteristics: pooled data from five phase III trials of SC golimumab in RA, PsA and AS
Characteristic Placebo±MTX Golimumab 50 mg±MTX Golimumab 100 mg±MTX Total
Randomised patients, N 639 685 979 2303
Women, n (%) 442 (69.2) 413 (60.3) 660 (67.4) 1515 (65.8)
Race, n (%)
Asian 67 (10.5) 83 (12.1) 135 (13.8) 285 (12.4)
Black 18 (2.8) 12 (1.8) 17 (1.7) 47 (2.0)
White 515 (80.6) 563 (82.2) 781 (79.8) 1859 (80.7)
Other 39 (6.1) 27 (3.9) 46 (4.7) 112 (4.9)
Age, years
Mean±SD 49.4±13.03 48.0±12.52 48.4±12.50 48.6±12.66
Median (IQR) 50.0 (41.0, 58.0) 48.0 (40.0, 57.0) 49.0 (40.0, 57.0) 49.0 (40.0, 57.0)
Disease duration, years
Mean±SD 8.2±8.73 7.7±8.12 7.2±7.75 7.6±8.15
Median (IQR) 4.8 (1.6, 11.6) 4.9 (1.4, 11.1) 4.5 (1.4, 10.1) 4.7 (1.4, 10.9)
CRP, mg/dL
Mean±SD 1.9±2.73 2.0±2.62 2.1±2.86 2.0±2.76
Median (IQR) 1.0 (0.3, 2.3) 0.9 (0.3, 2.4) 0.9 (0.3, 2.6) 0.9 (0.3, 2.4)
HAQ-DI in RA and PsA, 0–3*, N 559 542 831 1932
Mean±SD 1.4±0.67 1.4±0.70 1.4±0.68 1.4±0.68
Median (IQR) 1.4 (1.0, 1.9) 1.4 (0.9, 1.9) 1.4 (0.9, 1.9) 1.4 (0.9, 1.9)
DAS28-CRP in RA pts only, N 448 398 688 1534
Mean±SD 5.6±1.04 5.8±1.09 5.6±1.03 5.7±1.05
Median (IQR) 5.6 (4.8, 6.3) 5.8 (5.0, 6.5) 5.6 (4.9, 6.4) 5.7 (4.9, 6.4)
BASDAI >4 in AS pts, n/N (%) 75/78 (96.2) 130/138 (94.2) 135/140 (96.4) 340/356 (95.5)
MTX use in RA and PsA†
Number of MTX-treated patients 156 174 169 499
Mean dose±SD (mg) 16.0±5.01 16.0±5.30 16.3±5.33 16.1±5.21
Median dose (IQR) (mg) 15.0 (12.5, 20.0) 15.0 (12.5, 20.0) 15.0 (12.5, 20.0) 15.0 (12.5, 20.0)
Oral corticosteroid use in RA and PsA†
Number of corticosteroid-treated patients 270 260 413 943
Mean dose±SD (mg) 6.6±2.59 6.8±2.70 6.8±2.60 6.8±2.62
Median dose (IQR) (mg) 5.0 (5.0, 10.0) 6.0 (5.0, 10.0) 5.0 (5.0, 10.0) 5.0 (5.0, 10.0)
*HAQ-DI data were not collected in the GO-RAISE golimumab trial conducted in patients with AS.
†MTX use at baseline was not allowed in the GO-BEFORE golimumab trial in MTX-naïve patients with RA; MTX and oral corticosteroid use was very limited in patients with AS and are
thus summarised only for patients with RA and PsA.
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, 28-joint Disease Activity Score using CRP; HAQ-DI, Health
Assessment Questionnaire-Disability Index; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SC, subcutaneous.
Clinical and epidemiological research
Kay J, et al. Ann Rheum Dis 2015;74:538–546. doi:10.1136/annrheumdis-2013-204195 541
group.bmj.com on May 4, 2015 - Published by http://ard.bmj.com/Downloaded from 
placebo or golimumab 50 mg. The incidence (95% CI) of demye-
lination for golimumab 100 mg was 0.12 (0.03 to 0.30)/100
pt-yrs; this 95% CI was contained within that for placebo (table 5).
There were few hepatobiliary AEs up to wk 16 (table 4). Up
to wk 160, ﬁve patients developed a hepatobiliary SAE with
alanine aminotransferase (ALT) ≥3× the upper limit of normal
(ULN). Two patients (one with RA and one with AS) had chole-
lithiasis, one AS patient had hepatic steatosis, one AS patient
(with concomitant methotrexate (MTX) and indomethacin use
and recent alcohol use) had asymptomatic ALT and aspartate
aminotransferase elevations >5×ULN after the ﬁrst two doses
of golimumab 100 mg that resolved after golimumab discon-
tinuation, and one RA patient had investigator-reported hepatitis
that resulted in acute hepatic failure (with both events reported
as being of unknown cause by the investigator). This patient
experienced bleeding after liver biopsy and subsequently died.
Possible confounding factors included recent initiation of methi-
masole and history of herbal medicine use.
Although a higher proportion of patients (6.7%) and injec-
tions (1.4%) had an ISR associated with golimumab 100 mg
than with placebo (2.2% and 0.5%, respectively) or golimumab
50 mg (4.7% and 0.8%, respectively), no ISR was severe,
serious, or led to permanent discontinuation of the study agent
up to wk 16. Similar ﬁndings were observed up to wk 160, with
only one patient/injection (golimumab 100 mg) having a severe
ISR (table 4). An additional patient (golimumab 100 mg
+MTX) developed a serious ISR (moderate injection-site ery-
thema) that resulted in discontinuation of the study agent 1 day
after the 52-week visit. This patient had detectable antibodies to
golimumab.
Table 4 Safety findings up to week 16 and week 160: pooled data from five phase III studies of SC golimumab in rheumatological indications
(RA, PsA and AS)
Week 16 (placebo-controlled) Week 160
Placebo±MTX
Golimumab
50 mg±MTX
Golimumab
100 mg±MTX Placebo±MTX
Golimumab
50 mg±MTX
Golimumab
100 mg±MTX
Number of treated patients* 639 683 977 639 1249 1501
Patients with ≥1 AE 410 (64.2) 464 (67.9) 642 (65.7) 470 (73.6) 1069 (85.6) 1302 (86.7)
Most common AE†
Upper respiratory tract infection 37 (5.8) 51 (7.5) 69 (7.1) 56 (8.8) 263 (21.1) 346 (23.1)
Nasopharyngitis 31 (4.9) 37 (5.4) 54 (5.5) 42 (6.6) 167 (13.4) 219 (14.6)
Nausea 28 (4.4) 35 (5.1) 51 (5.2) 51 (8.0) 104 (8.3) 159 (10.6)
Cough – – – 38 (5.9) 124 (9.9) 149 (9.9)
Headache – – – 38 (5.9) 114 (9.1) 149 (9.9)
Back pain – – – 22 (3.4) 110 (8.8) 146 (9.7)
Bronchitis – – – 24 (3.8) 113 (9.0) 145 (9.7)
Sinusitis – – – 16 (2.5) 101 (8.1) 142 (9.5)
Hypertension – – – 16 (2.5) 84 (6.7) 135 (9.0)
Diarrhoea – – – 37 (5.8) 92 (7.4) 123 (8.2)
Injection-site erythema – – – 7 (1.1) 56 (4.5) 113 (7.5)
Urinary tract infection – – – 19 (3.0) 70 (5.6) 109 (7.3)
ALT increased – – – 33 (5.2) 108 (8.6) 107 (7.1)
RA – – – 25 (3.9) 58 (4.6) 107 (7.1)
Fatigue – – – 25 (3.9) 66 (5.3) 101 (6.7)
Rash – – – 23 (3.6) 62 (5.0) 88 (5.9)
Pharyngitis – – – 16 (2.5) 57 (4.6) 80 (5.3)
Influenza – – – 15 (2.3) 47 (3.8) 77 (5.1)
AST increased – – – 23 (3.6) 76 (6.1) 72 (4.8)
Patients with ≥1 SAE 31 (4.9) 30 (4.4) 35 (3.6) 57 (8.9) 192 (15.4) 325 (21.7)
Treatment discontinued due to ≥1 AE 18 (2.8) 18 (2.6) 18 (1.8) 31 (4.9) 92 (7.4) 158 (10.5)
Injection-site reactions
Patients with reactions‡ 14 (2.2) 32 (4.7) 65 (6.7) 18 (2.8) 107 (8.6) 174 (11.6)
Mild 14 (2.2) 32 (4.7) 64 (6.6) 18 (2.8) 102 (8.2) 169 (11.3)
Moderate 0 (0.0) 1 (0.1) 3 (0.3) 0 (0.0) 11 (0.9) 18 (1.2)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Patients with ≥1 hepatobiliary AE§ 0 (0.0) 1 (0.1) 1 (0.1) 1 (0.2) 3 (0.2) 5 (0.3)
ALT ≥3×ULN and bilirubin ≥2×ULN 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.2) 1 (0.1) 2 (0.1)
ALT ≥3×ULN and serious hepatobiliary AE 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 2 (0.2) 3 (0.2)
Data shown are number (%) of patients.
*Patients may appear in ≥1 treatment column.
†Defined as AE occurring in ≥5% of patients in any treatment group up to week 16 or week 160. Common AEs are presented in decreasing order of frequency in the golimumab
100 mg group up to week 160. AEs with ‘–’ did not meet the criterion for ‘common’ at that time point.
‡Patients may have reported ≥1 injection-site reaction.
§Hepatobiliary AE defined as ALT ≥3×ULN in combination with either bilirubin ≥2×ULN or the occurrence of an AE within the hepatobiliary system-organ class of the Medical
dictionary for regulatory activities that was classified as serious by the investigator in accordance with regulatory guidelines. For the latter criterion, two patients (one RA, one AS) had
cholelithiasis, one RA patient had hepatitis leading to acute hepatic failure of unknown cause and ultimately death, one AS patient had hepatic stenosis, and one AS patient had
hepatitis.
AE, adverse event; ALT, alanine aminotransferase; AS, ankylosing spondylitis; AST, aspartate aminotransferase; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis;
SAE, serious adverse event; SC, subcutaneous; ULN, upper limit of normal.
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Table 5 Incidences of rare safety events during the placebo-controlled period and up to week 160: pooled data from phase IIb and phase III studies of SC golimumab in rheumatological indications
(RA, PsA and AS)
Placebo-controlled period* Week 160
Placebo±MTX Golimumab 50 mg±MTX Golimumab 100 mg±MTX Placebo±MTX Golimumab 50 mg±MTX Golimumab 100 mg±MTX
Number of treated patients† 674 750 1044 674 1317 1571
Death, n (%) 1 (0.1) 1 (0.1) 3 (0.3) 1 (0.1) 7 (0.5) 14 (0.9)
Incidence per 100 pt-yrs (95% CI) 0.32 (0.01 to 1.79) 0.27 (0.01 to 1.53) 0.52 (0.11 to 1.53) 0.28 (0.01 to 1.56) 0.30 (0.12 to 0.62) 0.41 (0.23 to 0.69)
Serious infection, n (%) 17 (2.5) 12 (1.6) 27 (2.6) 17 (2.5) 57 (4.3) 117 (7.4)
Incidence per 100 pt-yrs (95% CI) 5.50 (3.21 to 8.81) 3.31 (1.71 to 5.78) 4.76 (3.14 to 6.92) 5.31 (3.20 to 8.30) 3.03 (2.36 to 3.82) 5.09 (4.36 to 5.90)
Tuberculosis, n (%) 0 (0.0) 2 (0.3) 0 (0.0) 0 (0.0) 4 (0.3) 12 (0.8)
Incidence per 100 pt-yrs (95% CI) 0.00 (0.00 to 0.96) 0.55 (0.07 to 1.98) 0.00 (0.00 to 0.52) 0.00 (0.00 to 0.84) 0.17 (0.05 to 0.44) 0.35 (0.18 to 0.62)
Opportunistic infection, n (%)‡ 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 3 (0.2) 8 (0.5)
Incidence per 100 pt-yrs (95% CI) 0.00 (0.00 to 0.96) 0.00 (0.00 to 0.82) 0.17 (0.00 to 0.97) 0.00 (0.00 to 0.84) 0.13 (0.03 to 0.38) 0.24 (0.10 to 0.46)
Malignancy
All malignancies, n (%) 6 (0.9) 3 (0.4) 10 (1.0) 7 (1.0) 29 (2.2) 38 (2.4)
Incidence per 100 pt-yrs (95% CI) 1.93 (0.71 to 4.21) 0.82 (0.17 to 2.41) 1.75 (0.84 to 3.21) 1.97 (0.79 to 4.05) 1.26 (0.84 to 1.81) 1.13 (0.80 to 1.55)
SIR (95% CI)§ vs SEER database 1.07 (0.13 to 3.87) 0.97 (0.12 to 3.49) 1.25 (0.34 to 3.21) 0.94 (0.11 to 3.38) 1.48 (0.89 to 2.31) 0.99 (0.61 to 1.53)
Non-melanoma skin cancer, n (%) 4 (0.6) 1 (0.1) 6 (0.6) 5 (0.7) 10 (0.8) 18 (1.1)
Incidence per 100 pt-yrs (95% CI) 1.29 (0.35 to 3.30) 0.27 (0.01 to 1.53) 1.05 (0.38 to 2.28) 1.40 (0.46 to 3.28) 0.43 (0.21 to 0.80) 0.53 (0.32 to 0.84)
Lymphoma, n (%) 0 (0.0) 0 (0.0) 2 (0.2) 0 (0.0) 1 (0.08)¶ 6 (0.4)**
Incidence per 100 pt-yrs (95% CI) 0.00 (0.00 to 0.96) 0.00 (0.00 to 0.82) 0.35 (0.04 to 1.26) 0.00 (0.00 to 0.84) 0.04 (0.00 to 0.24) 0.18 (0.06 to 0.38)
SIR (95% CI)§ vs SEER database 0.00 (0.00 to 36.43) 0.00 (0.00 to 32.66) 14.13 (1.71 to 51.03) 0.00 (0.00 to 31.98) 1.71 (0.04 to 9.55) 6.69 (2.45 to 14.56)
Demyelinating disorder, n (%) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 3 (0.2)
Incidence per 100 pt-yrs (95% CI) 0.00 (0.00 to 0.96) 0.00 (0.00 to 0.82) 0.17 (0.00 to 0.97) 0.00 (0.00 to 0.84) 0.00 (0.00 to 0.13) 0.12 (0.03 to 0.30)
*The controlled study period could extend up to week 52 per trial design.
†Patients may appear in ≥1 treatment column.
‡Identified events included histoplasmosis, listeria sepsis, oesophageal candidiasis, pneumonia legionella, coccidioidomycosis, eye infection toxoplasmal, Pneumocystis jiroveci pneumonia and Mycobacterium kansasii infection.
§95% CIs not containing 1 (in bold) indicate a significant difference from the SEER database.
¶This patient had AS.
**All six patients had RA. Two patients were diagnosed with lymphoma during the placebo-controlled period; the other four were diagnosed with lymphoma after the placebo-controlled period and by week 160.
AS, ankylosing spondylitis; MTX, methotrexate; PsA, psoriatic arthritis; pt-yrs, patient-years; RA, rheumatoid arthritis; SC, subcutaneous; SEER, Surveillance, Epidemiology and End Results; SIR, standardised incidence ratio.
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DISCUSSION
We assessed SC golimumab safety up to 3 years by pooling data
from ﬁve pivotal phase III trials in patients with active RA, PsA
or AS. Each study included a placebo-controlled period, fol-
lowed by uncontrolled study periods up to wk 160, during
which all patients received golimumab 50 or 100 mg every
4 weeks; the golimumab dose could be adjusted at the investiga-
tor’s discretion during the trials’ long-term extensions. In
several studies, background MTX use was continued. Results of
these pooled safety analyses indicate that the overall SC golimu-
mab safety proﬁle remains consistent with those of other TNF
antagonists used in the treatment of patients with RA and other
immune-mediated inﬂammatory disorders,1–4 26 27 although the
incidence of lymphoma associated with the 100 mg golimumab
dose requires continued monitoring (see below). We also evalu-
ated AE incidences by indication and found that RA patients,
who comprised approximately two-thirds of this safety popula-
tion, largely drove the overall AE incidences.
The increased risk of serious and opportunistic infections
associated with TNF antagonist therapy has been well charac-
terised. The rates of serious infection among patients with RA
treated with biological agents in clinical trials and observational
studies typically range from 3 to 8/100 pt-yrs, and the rate of
infection associated with anti-TNF therapy is approximately
1.5–2.0-fold higher than that associated with non-biological
disease-modifying antirheumatic drug treatment.28–34 In this
pooled analysis, the incidence of serious infection was generally
consistent across the treatment groups, although the incidence
observed for golimumab 100 mg was numerically higher than
for golimumab 50 mg, but not for placebo, during the placebo-
controlled study periods. Serious infections also appeared to be
somewhat more common among patients for whom oral cor-
ticosteroid use was documented at baseline. The incidences of
tuberculosis and opportunistic infection were each numerically
higher with golimumab 100 mg than with golimumab 50 mg at
wk 160; the 95% CIs for both golimumab doses, however, fell
below or were contained within those for placebo.
The possible increased risk of serious infection with golimu-
mab 100 mg is consistent with that calculated in a meta-analysis
of 18 randomised, controlled, clinical trials of anti-TNF agents,
which included 8808 patients with RA who received recom-
mended doses of adalimumab (20 mg/week), etanercept (50 mg/
week) or inﬂiximab (0.375 mg/kg/week), or doses lower or
higher than recommended. While the odds of developing a
serious infection were not increased among patients who
received recommended anti-TNF doses, doses two to three
times higher than recommended by product labelling were asso-
ciated with an increased risk of serious infection.35
TNF is essential for the host defence against mycobacterial
infection, and patients receiving TNF antagonists are at
increased risk of tuberculosis re-activation.36 While the current
analysis did not deﬁnitively show an increase in tuberculosis
with up to 3 years of golimumab therapy, tuberculosis screening
is required before initiation of a patient on TNF antagonist
therapy. Details of tuberculosis screening test results in this goli-
mumab phase III programme have been published.37 38 Patients
identiﬁed as having latent tuberculosis must start isoniazid treat-
ment before beginning anti-TNF therapy. Even with treatment
for latent tuberculosis, however, patients should be observed
carefully for active tuberculosis.
The incidence of opportunistic infection was not signiﬁcantly
increased during up to 3 years of golimumab treatment.
However, histoplasmosis, coccidioidomycosis and pneumocystis
pneumonia are the most common opportunistic infections
observed with TNF antagonist treatment, and caution must be
exercised when initiating anti-TNF therapy for patients who
have lived in or travelled to regions with endemic infecting
organisms.
The mortality incidences observed in the pooled analysis of
golimumab safety data up to wk 160 (0.28–0.41/100 pt-yrs) are
somewhat lower than those of 1.1 and 1.6/100 pt-yrs derived
from observation of patients treated with TNF inhibitors in
national registries of Swedish RA patients.39 40 Nonetheless, the
generalisability of our results may be limited by exclusion of
patients with numerous comorbidities from the clinical trials
that contributed data to the pooled analyses.
Although the malignancy risk with anti-TNF therapy has been
a concern because of the role of TNF in inhibiting tumour
growth, this has not been borne out in studies of patients with
RA.41–43 There is, however, considerable evidence that long-
standing chronic inﬂammation in the very patients who receive
anti-TNF agents is itself related to an increased lymphoma
risk.44 Although the overall malignancy risk was not increased
with golimumab therapy, there was a higher incidence of lymph-
oma with golimumab 100 mg than with either golimumab
50 mg or placebo. However, the 95% CIs for both golimumab
doses were fully contained within those for placebo. Six of the
seven lymphoma cases observed in these golimumab studies
developed in patients with RA. Of the seven cases of lymphoma,
four occurred in the GO-AFTER study, which enrolled RA
patients who had previously received other TNF inhibitors and
had substantial disease activity at baseline.15 This is not unex-
pected, since the risk of developing lymphoma is higher among
RA patients with active inﬂammation for longer time periods44
and who are more likely to have previously received a TNF
antagonist, but is not associated with TNF inhibitor therapy
itself.45 Although the majority of lymphomas developed in
patients who received golimumab 100 mg, this may not be
unexpected given the possibility of escalating the dose from 50
to 100 mg in patients with persistently active disease and the
longer exposure of a greater number of patients to the 100 mg
dose. Golimumab treatment did not appear to increase the inci-
dence of NMSC, although such a risk has been identiﬁed with
other anti-TNF agents,42 46 and continued assessment is war-
ranted. The Surveillance, Epidemiology, and End Results (SEER)
database is the standard source for general population-based
cancer data in the USA; however, although patients from North
America (USA, N=622; Canada, N=340) comprised the largest
patient group from a single continent in the golimumab trials,
comparison of patients with rheumatic diseases from other geo-
graphic regions with those in the SEER database may limit the
interpretation of such ﬁndings.
TNF antagonism may be associated with demyelinating
disease,47 but the incidence is low among patients with rheum-
atic diseases.48 Demyelinating disorders were reported infre-
quently, with three cases observed among patients treated with
golimumab 100 mg (incidence 0.12 per 100 pt-yrs (95% CI
0.03 to 0.30)) and none among patients in other treatment
groups. Retrospective medical history revealed two of these
patients had symptoms before initiating golimumab therapy, one
of whom had no improvement of symptoms after cessation of
golimumab. The remaining two patients reported improvement
after stopping golimumab.
In addition to analytical limitations discussed, the duration of
placebo control in trials contributing data to these analyses was
relatively short. Thus, comparisons between the golimumab-
and placebo-treated groups beyond the placebo-controlled phase
must take into account that ‘placebo-treated’ patients may
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actually have received golimumab for most of the time. Results
may also be confounded by study design differences among the
phase III trials and different durations of follow-up across treat-
ment groups, as well as by the small number of events observed,
particularly of death, opportunistic infection, demyelination and
lymphoma. Between-dose comparisons are limited by the longer
duration of exposure to golimumab 100 mg and possible selec-
tion bias, whereby more patients with severe disease/inﬂamma-
tion might have had their golimumab dose escalated to the
100 mg limit.
In conclusion, the safety proﬁle of SC golimumab up to
3 years has remained largely consistent with those of other TNF
antagonists. Golimumab 100 mg, vs 50 mg, was possibly asso-
ciated with an increased incidence of lymphoma and other
infrequently occurring safety events. Pharmacovigilance con-
tinues up to 5 years in the large phase III clinical trials of goli-
mumab in rheumatological indications.
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